US Stock MarketDetailed Quotes

OCGN Ocugen

Watchlist
  • 0.9698
  • +0.0612+6.74%
Close Nov 27 16:00 ET
  • 0.9700
  • +0.0002+0.02%
Post 19:58 ET
282.52MMarket Cap-5104P/E (TTM)

About Ocugen Company

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Company Profile

SymbolOCGN
Company NameOcugen
Listing DateDec 3, 2014
Issue Price11.00
Founded2013
CEODr. Shankar Musunuri, M.B.A.,PhD
MarketNASDAQ
Employees65
Fiscal Year Ends12-31
Address11 Great Valley Parkway
CityMalvern
ProvincePennsylvania
CountryUnited States of America
Zip Code19355
Phone1-484-328-4701
Websitehttp://www.ocugen.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Shankar Musunuri, M.B.A.,PhD
  • Chairman of the Board and Chief Executive Officer
  • 7.66M
  • Dr. Huma Qamar, M.D.,PhD
  • Chief Medical Officer
  • --
  • Arun Upadhyay, PhD
  • Chief Scientific Officer and Head, Research, Development, and Medical
  • --
  • Ramesh Ramachandran
  • Principal Financial Officer and Chief Accounting Officer
  • --
  • Uday B. Kompella, PhD
  • Independent Director
  • 341.82K
  • Kirsten Castillo, M.B.A.
  • Independent Director
  • 348.18K
  • Dr. Prabhavathi Fernandes, PhD
  • Lead Independent Director
  • 357.60K
  • Dr. Marna C. Whittington, PhD
  • Independent Director
  • 649.56K
  • Dr. Junge Zhang, PhD
  • Independent Director
  • 335.56K
  • Michael Breininger, C.P.A.,M.B.A.
  • Corporate Controller
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data